-
1
-
-
65349133379
-
-
abstract]. XVI Int Symp Drugs Affect Lipid Metab. New York, NY, 2007.
-
O'Neill EA, Sparrow CP, Chen Y, Eveland S, Frantz-Wattley B, Milot D, Sinclair PJ, Ali A, Lu Z, Smith CJ, Taylor G, Thompson CF, Anderson MS, Cumiskey A, Rosa R, Strain J, Peterson LB. Identification and characterization of anacetrapib (MK-0859): a novel CETP inhibitor abstract]. XVI Int Symp Drugs Affect Lipid Metab. New York, NY, 2007.
-
Identification and Characterization of Anacetrapib (MK-0859): A Novel CETP Inhibitor
-
-
O'Neill, E.A.1
Sparrow, C.P.2
Chen, Y.3
Eveland, S.4
Frantz-Wattley, B.5
Milot, D.6
Sinclair, P.J.7
Ali, A.8
Lu, Z.9
Smith, C.J.10
Taylor, G.11
Thompson, C.F.12
Anderson, M.S.13
Cumiskey, A.14
Rosa, R.15
Strain, J.16
Peterson, L.B.17
-
2
-
-
48149106322
-
Torcetrapib-induced blood pressure elevation is independent of CETP inhibition and is accompanied by an increase in circulating aldosterone levels
-
abstract
-
Forrest MJ, Bloomfield D, Briscoe RJ, Brown PN, Cumiskey A-M, Ehrhart J, Hershey JC, Keller WJ, Ma X, McPherson HE, Messina E, Peterson LB, Sharif-Rodriquez W, Siegel PS, Sinclair PJ, Sparrow CP, Stevenson AS, Sun SY, Tsai C, Vargas H, Walker M, West SH, White V, Woltmann RF. Torcetrapib-induced blood pressure elevation is independent of CETP inhibition and is accompanied by an increase in circulating aldosterone levels abstract Br J Pharmacol 2008 154 : 1465 73.
-
(2008)
Br J Pharmacol
, vol.154
, pp. 1465-73
-
-
Forrest, M.J.1
Bloomfield, D.2
Briscoe, R.J.3
Brown, P.N.4
Cumiskey, A.-M.5
Ehrhart, J.6
Hershey, J.C.7
Keller, W.J.8
Ma, X.9
McPherson, H.E.10
Messina, E.11
Peterson, L.B.12
Sharif-Rodriquez, W.13
Siegel, P.S.14
Sinclair, P.J.15
Sparrow, C.P.16
Stevenson, A.S.17
Sun, S.Y.18
Tsai, C.19
Vargas, H.20
Walker, M.21
West, S.H.22
White, V.23
Woltmann, R.F.24
more..
-
3
-
-
65349137411
-
-
abstract]. XVI Int Symp Drugs Affect Lipid Metab. New York, NY, 2007.
-
Krishna R, Bergman A, Chen J, Cote J, Van Hoydonck P, Chavez-Eng C, Lutz R, Laethem T, Van Dyck K, Hilliard D, Laterza O, Snyder K, Jin B, Bloomfield DM, De Smet M, Van Bortel L, Gottesdiener K, Wagner JA. Pharmacokinetics and pharmacodynamics of single doses of MK-0859, a potent cholesteryl ester transfer protein (CETP) inhibitor, in healthy subjects abstract]. XVI Int Symp Drugs Affect Lipid Metab. New York, NY, 2007.
-
Pharmacokinetics and Pharmacodynamics of Single Doses of MK-0859, A Potent Cholesteryl Ester Transfer Protein (CETP) Inhibitor, in Healthy Subjects
-
-
Krishna, R.1
Bergman, A.2
Chen, J.3
Cote, J.4
Van Hoydonck, P.5
Chavez-Eng, C.6
Lutz, R.7
Laethem, T.8
Van Dyck, K.9
Hilliard, D.10
Laterza, O.11
Snyder, K.12
Jin, B.13
Bloomfield, D.M.14
De Smet, M.15
Van Bortel, L.16
Gottesdiener, K.17
Wagner, J.A.18
-
4
-
-
56549117314
-
Multiple-dose pharmacodynamics and pharmacokinetics of anacetrapib, a Potent Cholesteryl Ester Transfer Protein (CETP) inhibitor, in healthy subjects
-
Krishna R, Bergman A, Jin B, Fallon M, Cote J, Van Hoydonck P, Laethem T, Gendrano IN, Van Dyck K, Hilliard D, Laterza O, Snyder K, Chavez-Eng C, Lutz R, Chen J, Bloomfield DM, De Smet M, Van Bortel L, Gutierrez M, Al-Huniti N, Dykstra K, Gottesdiener KM, Wagner JA. Multiple-dose pharmacodynamics and pharmacokinetics of anacetrapib, a Potent Cholesteryl Ester Transfer Protein (CETP) inhibitor, in healthy subjects. Clin Pharmacol Ther 2008 84 : 679 83.
-
(2008)
Clin Pharmacol Ther
, vol.84
, pp. 679-83
-
-
Krishna, R.1
Bergman, A.2
Jin, B.3
Fallon, M.4
Cote, J.5
Van Hoydonck, P.6
Laethem, T.7
Gendrano, I.N.8
Van Dyck, K.9
Hilliard, D.10
Laterza, O.11
Snyder, K.12
Chavez-Eng, C.13
Lutz, R.14
Chen, J.15
Bloomfield, D.M.16
De Smet, M.17
Van Bortel, L.18
Gutierrez, M.19
Al-Huniti, N.20
Dykstra, K.21
Gottesdiener, K.M.22
Wagner, J.A.23
more..
-
5
-
-
36549078679
-
Effect of the cholesteryl ester transfer protein inhibitor, anacetrapib, on lipoproteins in patients with dyslipidaemia and on 24-h ambulatory blood pressure in healthy individuals: Two double-blind, randomised placebo-controlled phase i studies
-
Krishna R, Anderson MS, Bergman A, Jin B, Fallon M, Cote J, Rosko K, Chavez-Eng C, Lutz R, Bloomfield DM, Gutierrez M, Doherty J, Bieberdorf F, Chodakewitz J, Gottesdiener K, Wagner JA. Effect of the cholesteryl ester transfer protein inhibitor, anacetrapib, on lipoproteins in patients with dyslipidaemia and on 24-h ambulatory blood pressure in healthy individuals: two double-blind, randomised placebo-controlled phase I studies. Lancet 2007 370 : 1907 1914.
-
(2007)
Lancet
, vol.370
, pp. 1907-1914
-
-
Krishna, R.1
Anderson, M.S.2
Bergman, A.3
Jin, B.4
Fallon, M.5
Cote, J.6
Rosko, K.7
Chavez-Eng, C.8
Lutz, R.9
Bloomfield, D.M.10
Gutierrez, M.11
Doherty, J.12
Bieberdorf, F.13
Chodakewitz, J.14
Gottesdiener, K.15
Wagner, J.A.16
-
6
-
-
65349103382
-
-
abstract]. American Association of Pharmaceutical Scientists Annual Meeting, Anaheim, CA, 2007.
-
Bergman A, Dykstra K, Al-Huniti N, Fallon M, Lutz R, Chavez-Eng C, Jin B, Hartford A, Cote J, Hilliard D, Laethem T, Van Hoydonck P, Snyder K, Van Dyck K, Stone J, Lasseter KC, Van Bortel L, Wagner J, Krishna R. Optimizing dose selection using population PK/PD modeling and simulation for the CETP inhibitor anacetrapib (MK-0859) in healthy subjects abstract]. American Association of Pharmaceutical Scientists Annual Meeting, Anaheim, CA, 2007.
-
Optimizing Dose Selection Using Population PK/PD Modeling and Simulation for the CETP Inhibitor Anacetrapib (MK-0859) in Healthy Subjects
-
-
Bergman, A.1
Dykstra, K.2
Al-Huniti, N.3
Fallon, M.4
Lutz, R.5
Chavez-Eng, C.6
Jin, B.7
Hartford, A.8
Cote, J.9
Hilliard, D.10
Laethem, T.11
Van Hoydonck, P.12
Snyder, K.13
Van Dyck, K.14
Stone, J.15
Lasseter, K.C.16
Van Bortel, L.17
Wagner, J.18
Krishna, R.19
-
7
-
-
65349141635
-
-
abstract]. XVI Int Symp Drugs Affect Lipid Metab (DALM). New York, NY, 2007.
-
Bloomfield DM, Carlson G, Sapre A, Tribble D, McKenney JM, Littlejohn TW, Sisk CM, Mitchel YB. Efficacy and safety of the CETP inhibitor MK-0859 in dyslipidemic patients abstract]. XVI Int Symp Drugs Affect Lipid Metab (DALM). New York, NY, 2007.
-
Efficacy and Safety of the CETP Inhibitor MK-0859 in Dyslipidemic Patients
-
-
Bloomfield, D.M.1
Carlson, G.2
Sapre, A.3
Tribble, D.4
McKenney, J.M.5
Littlejohn, T.W.6
Sisk, C.M.7
Mitchel, Y.B.8
-
8
-
-
58149202372
-
Assessment of the CYP3A-mediated drug interaction potential of anacetrapib, a potent cholesteryl ester transfer protein (CETP) inhibitor, in healthy subjects
-
Krishna R, Bergman AJ, Jin B, Garg A, Roadcap BA, Chiou RH, Dru JD, Cote J, Laethem T, Vets E, Avery P, Gottesdiener KM, Wagner JA. Assessment of the CYP3A-mediated drug interaction potential of anacetrapib, a potent cholesteryl ester transfer protein (CETP) inhibitor, in healthy subjects. J Clin Pharmacol 2009 49 : 80 7.
-
(2009)
J Clin Pharmacol
, vol.49
, pp. 80-7
-
-
Krishna, R.1
Bergman, A.J.2
Jin, B.3
Garg, A.4
Roadcap, B.A.5
Chiou, R.H.6
Dru, J.D.7
Cote, J.8
Laethem, T.9
Vets, E.10
Avery, P.11
Gottesdiener, K.M.12
Wagner, J.A.13
-
10
-
-
65349180621
-
-
Merck & Co., Inc. Whitehouse Station, NJ. Merck & Co., Inc.
-
Merck & Co., Inc. Zocor (Simvastatin) Product Circular. Whitehouse Station, NJ : Merck & Co., Inc., 2004.
-
(2004)
Zocor (Simvastatin) Product Circular.
-
-
-
11
-
-
0026341760
-
Long-term efficacy and safety of simvastatin alone and in combination therapy in treatment of hypercholesterolemia
-
Mölgaard J, Lundh BL, van Schenck H, Olsson AG. Long-term efficacy and safety of simvastatin alone and in combination therapy in treatment of hypercholesterolemia. Atherosclerosis 1991 91 : S21 8.
-
(1991)
Atherosclerosis
, vol.91
, pp. 21-8
-
-
Mölgaard, J.1
Lundh, B.L.2
Van Schenck, H.3
Olsson, A.G.4
-
12
-
-
0031670167
-
Erythromycin and verapamil considerably increase serum simvastatin and simvastatin acid concentrations
-
Kantola T, Kivistö KT, Neuvonen PT. Erythromycin and verapamil considerably increase serum simvastatin and simvastatin acid concentrations. Clin Pharmacol Ther 1998 64 : 177 82.
-
(1998)
Clin Pharmacol Ther
, vol.64
, pp. 177-82
-
-
Kantola, T.1
Kivistö, K.T.2
Neuvonen, P.T.3
-
13
-
-
0032886788
-
Concomitant use of cytochrome P450 3A4 inhibitors and simvastatin
-
Gruer PJK, Vega JM, Mercuri MF, Dobrinska MR, Tobert JA. Concomitant use of cytochrome P450 3A4 inhibitors and simvastatin. Am J Cardiol 1999 84 : 811 5.
-
(1999)
Am J Cardiol
, vol.84
, pp. 811-5
-
-
Gruer, P.J.K.1
Vega, J.M.2
Mercuri, M.F.3
Dobrinska, M.R.4
Tobert, J.A.5
-
14
-
-
18544390238
-
Pharmacodynamic interaction between the new selective cholesterol absorption inhibitor ezetimibe and simvastatin
-
Kosoglou T, Meyer I, Veltri EP, Statkevich P, Yang B, Zhu Y, Mellars L, Maxwell SE, Patrick JE, Cutler DL, Batra V, Affrime MB. Pharmacodynamic interaction between the new selective cholesterol absorption inhibitor ezetimibe and simvastatin. Br J Clin Pharmacol 2002 54 : 309 19.
-
(2002)
Br J Clin Pharmacol
, vol.54
, pp. 309-19
-
-
Kosoglou, T.1
Meyer, I.2
Veltri, E.P.3
Statkevich, P.4
Yang, B.5
Zhu, Y.6
Mellars, L.7
Maxwell, S.E.8
Patrick, J.E.9
Cutler, D.L.10
Batra, V.11
Affrime, M.B.12
-
15
-
-
33846505675
-
Torcetrapib combined with atorvastatin raises HDL-C, lowers LDL-C, and is well tolerated: Results from a phase 2 dose-ranging clinical trial
-
Suppl.
-
Thuren T, Longcore A, Powell C. Torcetrapib combined with atorvastatin raises HDL-C, lowers LDL-C, and is well tolerated: results from a phase 2 dose-ranging clinical trial. Circulation 2005 112 (17 Suppl. II-179.
-
(2005)
Circulation
, vol.112
, Issue.17
, pp. 179
-
-
Thuren, T.1
Longcore, A.2
Powell, C.3
-
16
-
-
33644812717
-
Model-based development of gemcabene, a new lipid-altering agent
-
Mandema JW, Hermann D, Wang W, Sheiner T, Milad M, Bakker-Arkema R, Hartman D. Model-based development of gemcabene, a new lipid-altering agent. AAPS J 2005 7 : E513 22.
-
(2005)
AAPS J
, vol.7
, pp. 513-22
-
-
Mandema, J.W.1
Hermann, D.2
Wang, W.3
Sheiner, T.4
Milad, M.5
Bakker-Arkema, R.6
Hartman, D.7
-
17
-
-
0024307596
-
Comparative effects of simvastatin and cholestyramine in treatment of patients with hypercholesterolaemia
-
Mölgaard J, von Schenck H, Olsson AG. Comparative effects of simvastatin and cholestyramine in treatment of patients with hypercholesterolaemia. Eur J Clin Pharmacol 1989 36 : 455 60.
-
(1989)
Eur J Clin Pharmacol
, vol.36
, pp. 455-60
-
-
Mölgaard, J.1
Von Schenck, H.2
Olsson, A.G.3
-
18
-
-
33644839739
-
Effects of the cholesteryl ester transfer protein inhibitor torcetrapib on apolipoprotein B100 metabolism in humans
-
Millar JS, Brousseau M, Diffenderfer MR, Hugh P, Barrett R, Welty FK, Faruqi A, Wolfe ML, Nartsupha C, Digenio A, Mancuso JP, Dolnikowski GG, Schaefer EJ, Rader DJ. Effects of the cholesteryl ester transfer protein inhibitor torcetrapib on apolipoprotein B100 metabolism in humans. Arterioscler Thromb Vasc Biol 2006 26 : 1350 6.
-
(2006)
Arterioscler Thromb Vasc Biol
, vol.26
, pp. 1350-6
-
-
Millar, J.S.1
Brousseau, M.2
Diffenderfer, M.R.3
Hugh, P.4
Barrett, R.5
Welty, F.K.6
Faruqi, A.7
Wolfe, M.L.8
Nartsupha, C.9
Digenio, A.10
Mancuso, J.P.11
Dolnikowski, G.G.12
Schaefer, E.J.13
Rader, D.J.14
|